Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chatbot 'Penny' aims to reconnect cancer survivors with life-saving follow-up care

NCT ID NCT05863702

Knowledge-focused Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a chatbot named Penny that sends text messages to help adult survivors of childhood or young adult cancers schedule follow-up appointments, lab work, and scans. The goal was to see if survivors who had not been to a clinic in over three years would use the chatbot to reengage with care. Fifty-three survivors participated, and researchers tracked how many scheduled and kept their appointments over 16 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
chatbot (Penny)
What this could lead to
If successful, this chatbot could help more cancer survivors get the long-term follow-up care they need, potentially improving their health outcomes.
What could go wrong
This is a small feasibility study with only 53 participants, so results may not apply to everyone. The chatbot relies on text messaging, which may not work for all survivors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

53 people

The number who actually took part.

Started

Sep 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient (age \> 18 years), male or female, diagnosed with cancer as a child or as a young adult, between birth and 39 years of age * Patient possession of a mobile device that can receive SMS texts * Ability to respond to questions and engage with "Penny" in English * Ability to provide informed consent to participate in the study * Approval of the patient's oncology care team for the patient to be involved in the study Exclusion Criteria: * Anyone who does not meet the inclusion criteria * Patients with a history of thyroid cancer or skin cancers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Childhood cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

childhood malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Survivorship

Contacts and locations

Locations

  • Abramson Cancer Center of the University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.